Posted On: May 13, 2009
Botox and Dysport and Cerebral Palsy
Earlier this month the FDA requested that Botox and its newly approved competitor Dysport should carry black box warnings.
The main reason for this warning is the off label use of the drugs to treat spasticity in children with cerebral palsy.
These warnings come after the 2008 death of a child with cerebral palsy being treated for spasticity.
It is believed that children being treated for spasticity are given a higher dose of the drug than those being treated for cosmetic purposes thus presenting an extreme danger to the child.
For more information on the 2008 FDA warning please see my previous post.
